May 10, 2024
Never ones to shy away from a challenge, David Potter, MD, PhD, and his team at the Masonic Cancer Center are developing new therapies to target extra-tough breast cancer tumors. Using a class of diabetes drugs, researchers are working toward treatments to activate a patient’s immune system to fight particularly stubborn tumors. The team hopes to begin human clinical trials soon. The Masonic Cancer Center is a Consortium Member Center.